Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC
Conditions: Advanced Hepatocellular Carcinoma (HCC) Interventions: Drug: WGI-0301 at MTD/RP2D dose IV infusion, QW; Drug: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW; Drug: Sorafenib 400 mg PO, BID continuously; Drug: Sorafenib 400 mg PO, BID Sponsors: Zhejiang Haichang Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Study